Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMX NASDAQ:KLRS NASDAQ:UPB NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMXImmix Biopharma$9.75+2.2%$9.34$1.87▼$11.61$505.73M0.12707,029 shs661,183 shsKLRSKalaris Therapeutics$5.08-1.4%$7.12$2.14▼$11.88$118.41M0.1594,588 shs41,396 shsUPBUpstream Bio$9.09+1.2%$9.09$7.25▼$33.68$488.96M1.28518,525 shs456,043 shsZURAZura Bio$4.79+5.5%$5.94$0.98▼$7.44$430.76M0.09647,867 shs1.05 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMXImmix Biopharma0.00%+6.83%+9.03%+41.54%+350.00%KLRSKalaris Therapeutics0.00%-6.70%-18.77%-38.25%+514,999,900.00%UPBUpstream Bio0.00%-2.18%-8.74%-65.73%+4.66%ZURAZura Bio0.00%-10.63%-20.35%-24.46%+267.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMXImmix Biopharma$9.75+2.2%$9.34$1.87▼$11.61$505.73M0.12707,029 shs661,183 shsKLRSKalaris Therapeutics$5.08-1.4%$7.12$2.14▼$11.88$118.41M0.1594,588 shs41,396 shsUPBUpstream Bio$9.09+1.2%$9.09$7.25▼$33.68$488.96M1.28518,525 shs456,043 shsZURAZura Bio$4.79+5.5%$5.94$0.98▼$7.44$430.76M0.09647,867 shs1.05 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMXImmix Biopharma0.00%+6.83%+9.03%+41.54%+350.00%KLRSKalaris Therapeutics0.00%-6.70%-18.77%-38.25%+514,999,900.00%UPBUpstream Bio0.00%-2.18%-8.74%-65.73%+4.66%ZURAZura Bio0.00%-10.63%-20.35%-24.46%+267.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMXImmix Biopharma 2.50Moderate Buy$18.2587.18% UpsideKLRSKalaris Therapeutics 2.71Moderate Buy$14.00175.59% UpsideUPBUpstream Bio 2.60Moderate Buy$39.00329.04% UpsideZURAZura Bio 2.67Moderate Buy$10.75124.43% UpsideCurrent Analyst Ratings BreakdownLatest KLRS, UPB, IMMX, and ZURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026UPBUpstream Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026IMMXImmix Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026KLRSKalaris Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$14.004/8/2026ZURAZura Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/30/2026IMMXImmix Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$14.00 ➝ $15.003/27/2026IMMXImmix Biopharma Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$23.003/27/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $15.003/27/2026UPBUpstream Bio EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ In-Line$15.003/25/2026IMMXImmix Biopharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.003/23/2026ZURAZura Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.003/20/2026ZURAZura Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$16.00 ➝ $15.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMXImmix BiopharmaN/AN/AN/AN/A$1.77 per shareN/AKLRSKalaris TherapeuticsN/AN/AN/AN/A$4.21 per shareN/AUPBUpstream Bio$2.85M173.57N/AN/A$6.29 per share1.45ZURAZura BioN/AN/AN/AN/A$1.38 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMXImmix Biopharma-$29.44M-$0.89N/AN/AN/AN/A-101.25%-73.39%6/3/2026 (Estimated)KLRSKalaris Therapeutics-$43.44M-$4.21N/AN/AN/AN/A-73.11%-43.56%N/AUPBUpstream Bio-$143.44M-$2.67N/AN/AN/A-5,026.03%-36.48%-35.38%N/AZURAZura Bio-$99.35M-$1.06N/AN/AN/AN/A-68.58%-55.89%N/ALatest KLRS, UPB, IMMX, and ZURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026Q1 2026IMMXImmix Biopharma-$0.2084N/AN/AN/AN/AN/A5/7/2026Q1 2026IMMXImmix Biopharma-$0.1450-$0.18-$0.0350-$0.18N/AN/A5/7/2026Q1 2026ZURAZura Bio-$0.17-$0.22-$0.05-$0.22N/AN/A3/26/2026Q4 2025UPBUpstream Bio-$0.73-$0.7860-$0.0560-$0.78$0.52 million$0.67 million3/25/2026Q4 2025IMMXImmix Biopharma-$0.16-$0.28-$0.12-$0.28N/AN/A3/17/2026Q4 2025KLRSKalaris Therapeutics-$0.56-$0.44+$0.12-$0.44N/AN/A3/16/2026Q4 2025ZURAZura Bio-$0.18-$0.49-$0.31-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMMXImmix BiopharmaN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMXImmix BiopharmaN/A10.0110.01KLRSKalaris TherapeuticsN/A12.2312.23UPBUpstream BioN/A26.1526.15ZURAZura BioN/A9.059.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMXImmix Biopharma11.26%KLRSKalaris Therapeutics66.05%UPBUpstream BioN/AZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipIMMXImmix Biopharma30.30%KLRSKalaris Therapeutics68.10%UPBUpstream Bio13.56%ZURAZura Bio14.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMXImmix Biopharma953.01 million36.95 millionOptionableKLRSKalaris Therapeutics11022.99 million7.33 millionN/AUPBUpstream Bio3854.42 million47.04 millionN/AZURAZura Bio394.88 million81.38 millionOptionableKLRS, UPB, IMMX, and ZURA HeadlinesRecent News About These CompaniesZura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by AnalystsMay 9 at 4:16 AM | marketbeat.comZura Bio (NASDAQ:ZURA) Releases Earnings Results, Misses Estimates By $0.05 EPSMay 7 at 10:49 PM | marketbeat.comZura Bio Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7 at 8:01 AM | businesswire.comZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | businesswire.comZura Bio (ZURA) to Release Earnings on ThursdayApril 30, 2026 | marketbeat.comZura Bio Limited Class AApril 24, 2026 | edition.cnn.comOne Zura Bio Insider Raised Their Stake In The Previous YearApril 23, 2026 | finance.yahoo.comZura Bio (NASDAQ:ZURA) Shares Down 5.3% - Time to Sell?April 20, 2026 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA)April 16, 2026 | theglobeandmail.comZura Bio: Momentum Is Real, But TibuSHIELD Needs To DeliverMarch 31, 2026 | seekingalpha.comZura Bio Reports Full Year 2025 Financial Results and Recent Corporate UpdatesMarch 19, 2026 | businesswire.comZura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World CongressMarch 5, 2026 | businesswire.comInsider Buying: Zura Bio (NASDAQ:ZURA) Major Shareholder Acquires 2,000,000 Shares of StockMarch 3, 2026 | insidertrades.comZura Bio to Participate in Upcoming Investor ConferencesMarch 2, 2026 | businesswire.comZura Bio Raises $144 Million To Advance Autoimmune Drug PipelineFebruary 27, 2026 | ventureburn.comVZura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesFebruary 27, 2026 | businesswire.comZura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsFebruary 25, 2026 | businesswire.comZura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsFebruary 24, 2026 | finance.yahoo.comZura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.February 23, 2026 | businesswire.comZura Bio Advances Tibulizumab Strategy in Autoimmune DiseasesFebruary 12, 2026 | theglobeandmail.comWedbush initiates coverage of Zura Bio (ZURA) with outperform recommendationFebruary 10, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKLRS, UPB, IMMX, and ZURA Company DescriptionsImmix Biopharma NASDAQ:IMMX$9.75 +0.21 (+2.20%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$9.26 -0.49 (-5.03%) As of 05/8/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Kalaris Therapeutics NASDAQ:KLRS$5.08 -0.07 (-1.36%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$5.05 -0.03 (-0.59%) As of 05/8/2026 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Upstream Bio NASDAQ:UPB$9.09 +0.11 (+1.22%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$9.11 +0.02 (+0.22%) As of 05/8/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.Zura Bio NASDAQ:ZURA$4.79 +0.25 (+5.51%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$4.88 +0.09 (+1.96%) As of 05/8/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
